在多发性硬化症中使用ocrelizumab的现实世界持久性:系统性审查
John L Petrie1, Charlie A Smith2, Donna Fountain1
1Putnam, Portland House, New Bridge Street West, Newcastle Upon Tyne, NE1 8AP, UK.
Neurology and therapy
|October 19, 2024
概括
现实世界的研究表明ocrelizumab的持续性与多发性硬化症的临床试验相似或更好. 由于不良事件而停止使用ocrelizumab的比例较低,与其他疾病修饰疗法相比,坚持治疗的比例更高.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 对多发性硬化症 (MS) 治疗ocrelizumab的临床试验数据显示,由于不良事件而导致的中止率较低.
- 现实世界患者群体与临床试验参与者不同,需要对现实世界数据进行评估.
- 了解治疗持续性和中止性对于有效管理MS至关重要.
研究的目的:
- 进行现实研究的系统文献综述 (SLR).
- 确定在复发性缓解性多发性硬化 (RRMS) 和初级渐进性多发性硬化 (PPMS) 中对ocrelizumab的停止和持续数据.
- 将现实世界中的ocrelizumab数据与关键临床试验结果进行比较.
主要方法:
- 在MEDLINE和Embase数据库中进行了搜索.
- 包括符合PICOS标准的相关现实研究.
- 只有英语文章才被考虑.
主要成果:
- 审查中包括了30项研究.
- 大多数研究报告了与临床试验结果相比或超过的真实世界奥克雷利祖马布持久性.
- 一项研究报告说,与临床试验相比,由于不良事件导致ocrelizumab的中止率更高.
- 与其他疾病修饰疗法 (DMT) 相比,ocrelizumab显示了更低的中止风险和更高的坚持.
结论:
- 在MS中使用ocrelizumab的真实世界持久性和停止数据通常是有利的.
- 奥克雷利祖马布在坚持和持久性方面可能比其他DMT具有优势.
- 这些发现支持治疗持续性的临床相关性,以改善MS管理的结果和成本效益.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:06Drug Clearance: Overview
57
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
57
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97